Ozempic study shows it can slow kidney disease

Novo Nordisk’s wight-loss ‘wonder drug’ has had another positive research breakthrough, with latest clinical data suggesting it also slows the progression of kidney disease and reduces the risk of death.

The research, published in the New England Journal of Medicine, was undertaken with patients with Type 2 diabetes and chronic kidney disease.

The study found that patients taking Ozempic had a 24% lower risk of severe kidney events and death from cardiovascular or kidney causes compared to those on placebo.

It involved around 3,500 participants over approximately 3.5 years, and it also showed that Ozempic also reduced the risk of heart attack and other major cardiovascular events by 18%.

According to expert commentators, quoted in media reports, suggest that the findings support the expansion of Ozempic’s label to include treatment for diabetic kidney disease.

This latest reports adds to the weight of research into the GLP-1 weight loss drugs and the other impacts that they’ve been seen including reducing the risk of heart attack, stroke, and other cardiovascular events.

The success of Ozempic and Wegovy has been the driving force behind Novo Nordisk’s soaring valuation.

Novo Nordisk shares are up 400% in recent years, and are up around 70% over the past twelve months. It is now Europe’s most valuable company at around $450 billion